Alex Leech is a Venture Partner at SV Health Investors having joined the SV Venture Partner Program in July 2019. He is currently CEO of Alchemab Therapeutics and a non-executive director and was the first CEO of Zarodex both SV portfolio companies.
Prior to joining SV, Alex was co-founder and Chief Executive Officer of neurodegeneration company Camphos Therapeutics Ltd. Prior to this, he was the Chief Executive Officer of Creabilis Therapeutics, a late clinical stage European dermatology and inflammation business. In 2016 Alex led the sale of Creabilis to Sienna Biopharmaceuticals Inc.
Alex has significant experience in managing research and development projects. Prior to joining Creabilis in 2011, he was Head of Operations at US based pain company Solace Pharmaceuticals Inc. He gained pharmaceutical R&D experience at Pfizer, including working as part of a small team that led the restructuring of the Pfizer’s global drug development capabilities. Early in his career, Alex gained valuable management and commercial experience at Ford Motor Company and the Visteon Corporation.
BEng (Hons) in Mechanical Engineering from the University of Sussex, UK; MBA from Henley Management College, UK.